# Phloroglucinaldehyde Alleviates High-Fat-Diet-Induced MAFLD via Its Antioxidant and Anti-Inflammatory Properties

**Authors:** Jijun Tan, Jianhua He, Hongfu Zhang, Shusong Wu

PMC · DOI: 10.3390/foods15030437 · 2026-01-25

## TL;DR

Phloroglucinaldehyde, a compound from berries, reduces fatty liver disease by fighting oxidative stress and inflammation in mice and cells.

## Contribution

Phloroglucinaldehyde's specific lipid-regulating, antioxidant, and anti-inflammatory effects in MAFLD are newly demonstrated.

## Key findings

- PGA reduced body weight, hepatic steatosis, and liver enzymes in HFD-induced MAFLD models.
- PGA down-regulated 46 lipid species, mainly triglycerides with long-chain fatty acids.
- PGA enhanced antioxidant activity and reduced pro-inflammatory cytokines and endotoxins.

## Abstract

Metabolic associated fatty liver disease (MAFLD), redefined from non-alcoholic fatty liver disease (NAFLD), is a global health concern driving the search for dietary interventions based on natural compounds. Phloroglucinaldehyde (PGA), a primary phenolic metabolite of the widely consumed anthocyanin cyanidin-3-glucoside (C3G) found in berries and other fruits, has emerged as a promising candidate due to its potential higher bioavailability than its parent compound. This study investigates the protective effects of PGA against high-fat diet (HFD)-induced MAFLD. Using both in vitro (LO2 cells) and in vivo (C57BL/6J mice) models, we found that PGA administration significantly attenuated body weight gain and hepatic steatosis, while reducing serum levels of TG, TC, liver transaminases (AST & ALT), and insulin resistance (p < 0.05). Further liver lipidomic profiling revealed that PGA supplementation specifically down-regulated 46 lipid species (p < 0.05), predominantly triglycerides characterized by long-chain and very-long-chain saturated fatty acids. Mechanistically, PGA enhanced the hepatic antioxidant capacity by increasing superoxide dismutase (SOD) activity (p < 0.05) and decreasing malondialdehyde (MDA) (p < 0.05) and exerted anti-inflammatory effects by reducing pro-inflammatory cytokines (IL-6, TNF, MCP-1) (p < 0.05) and endotoxin levels (p < 0.05). Correlation analyses further linked the down-regulated lipids to improvements in oxidative stress and inflammation. Our findings underscore that PGA, a key bioactive metabolite derived from dietary anthocyanins, alleviates MAFLD through its potent antioxidant and anti-inflammatory properties, highlighting its potential as a functional food ingredient or nutraceutical for metabolic health.

## Linked entities

- **Proteins:** IL6 (interleukin 6), TNF (tumor necrosis factor), CCL2 (C-C motif chemokine ligand 2)
- **Chemicals:** Phloroglucinaldehyde (PubChem CID 68099), cyanidin-3-glucoside (PubChem CID 197081), malondialdehyde (PubChem CID 10964)
- **Diseases:** non-alcoholic fatty liver disease (MONDO:0013209)

## Full-text entities

- **Genes:** SLC17A5 (solute carrier family 17 member 5) [NCBI Gene 26503] {aka AST, ISSD, NSD, SD, SIALIN, SIASD}, CCL2 (C-C motif chemokine ligand 2) [NCBI Gene 6347] {aka GDCF-2, HC11, HSMCR30, MCAF, MCP-1, MCP1}, SOD1 (superoxide dismutase 1) [NCBI Gene 6647] {aka ALS, ALS1, HEL-S-44, IPOA, SOD, STAHP}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}
- **Diseases:** MAFLD (MESH:D005234), Inflammatory (MESH:D007249), weight gain (MESH:D015430), insulin resistance (MESH:D007333), NAFLD (MESH:D065626)
- **Chemicals:** C3G (MESH:C462279), TG (MESH:D013866), MDA (MESH:D008315), triglycerides (MESH:D014280), Fat (MESH:D005223), TC (MESH:D013667), anthocyanin (MESH:D000872), lipid (MESH:D008055), PGA (MESH:C535196), saturated fatty acids (MESH:D005227)
- **Species:** Mus musculus (house mouse, species) [taxon 10090]

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12896450/full.md

---
Source: https://tomesphere.com/paper/PMC12896450